TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.
Fusen Pharmaceutical Co., Ltd. has announced the approval of its ‘Metformin Empagliflozin Tablets (I)’ by the National Medical Products Administration of China for the treatment of type 2 diabetes. This new product, which combines Metformin and Empagliflozin, is expected to enhance the company’s product pipeline in diabetes care, offering a synergistic hypoglycemic effect and better patient tolerance. The approval aligns with China’s national health goals, potentially increasing demand for diabetes medications and strengthening Fusen’s market position in the industry.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. The company, along with its subsidiaries, develops and markets pharmaceutical products, with a particular emphasis on diabetes treatment.
Average Trading Volume: 193,565
Technical Sentiment Signal: Hold
Current Market Cap: HK$268.4M
For an in-depth examination of 1652 stock, go to TipRanks’ Overview page.